pharma · Glaucoma · Macular Edema
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Allergan Pharmaceuticals International drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Sensory organs (S01) compound in Allergan Pharmaceuticals International's portfolio. Molecular target: Vascular endothelial growth factor A, long form.
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
Musculo-skeletal system (M03) compound in Allergan Pharmaceuticals International's portfolio. Molecular target: Synaptosomal-associated protein 25.
Dermatologicals (D11) compound in Allergan Pharmaceuticals International's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA gyrase.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.
US regulatory status: approved. Molecular target: Cyclooxygenase.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.
Development asset linked to Allergan Pharmaceuticals International in public FDA and regional records.